Cargando…

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial

PURPOSE: To investigate the safety and toxicity of percutaneous hepatic perfusion with melphalan (M-PHP) with the Delcath Systems’ second-generation (GEN 2) filter and compare the outcomes with historical data from studies using the first-generation filter. MATERIALS AND METHODS: A prospective, sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meijer, T. Susanna, Burgmans, Mark C., Fiocco, Marta, de Geus-Oei, Lioe-Fee, Kapiteijn, Ellen, de Leede, Eleonora M., Martini, Christian H., van der Meer, Rutger W., Tijl, Fred G. J., Vahrmeijer, Alexander L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502784/ https://www.ncbi.nlm.nih.gov/pubmed/30767147 http://dx.doi.org/10.1007/s00270-019-02177-x

Ejemplares similares

Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer
por: Meijer, T. Susanna, et al.
Publicado: (2022)

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
por: Moeslein, Fred M., et al.
Publicado: (2014)

Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies
por: Burgmans, Mark C., et al.
Publicado: (2015)

ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma
por: Poels, Thomas T., et al.
Publicado: (2021)

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
por: Tong, T. M. L., et al.
Publicado: (2022)

The Value of (18)F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review
por: Bijlstra, Okker D., et al.
Publicado: (2022)

Ablation margin quantification after thermal ablation of malignant liver tumors: How to optimize the procedure? A systematic review of the available evidence
por: Hendriks, Pim, et al.
Publicado: (2023)

Predictive and prognostic value of FDG-PET
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2008)

Editorial on Special Issue “Quantitative PET and SPECT”
por: van Velden, Floris H. P., et al.
Publicado: (2022)

Nanocarriers as a Tool for the Treatment of Colorectal Cancer
por: C. de S. L. Oliveira, Ana Luiza, et al.
Publicado: (2021)

Methodological considerations in quantification of oncological FDG PET studies
por: Vriens, Dennis, et al.
Publicado: (2009)

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma
por: Gilles, Rozemarie, et al.
Publicado: (2011)

PET/CT in Patients with Breast Cancer Treated with Immunotherapy
por: Vaz, Sofia C., et al.
Publicado: (2023)

FDG-PET/CT based response-adapted treatment
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2012)

Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas
por: Kleiburg, Fleur, et al.
Publicado: (2023)

Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging
por: Houvast, Ruben D., et al.
Publicado: (2020)

Adding the temporal domain to PET radiomic features
por: Noortman, Wyanne A., et al.
Publicado: (2020)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
por: Dotinga, Maaike, et al.
Publicado: (2022)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring (18)F-FDG-PET/CT
por: Meijer, Tineke W.H., et al.
Publicado: (2018)

Intraoperative Near-Infrared Fluorescence Imaging with Indocyanine Green for Identification of Gastrointestinal Stromal Tumors (GISTs), a Feasibility Study
por: Kalisvaart, Gijsbert M., et al.
Publicado: (2022)

The current role of nuclear medicine in breast cancer
por: Vaz, Sofia C., et al.
Publicado: (2023)

FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial
por: de Koster, Elizabeth J., et al.
Publicado: (2022)

Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer
por: Heijmen, Linda, et al.
Publicado: (2015)

Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients
por: Govaert, Stephanie LA, et al.
Publicado: (2012)

Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report
por: Mooij, Christiaan F., et al.
Publicado: (2016)

Striatal dopamine synthesis capacity in autism spectrum disorder and its relation with social defeat: an [(18)F]-FDOPA PET/CT study
por: Schalbroeck, Rik, et al.
Publicado: (2021)

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.
por: Honess, D. J., et al.
Publicado: (1985)

Cell-Based Tracers as Trojan Horses for Image-Guided Surgery
por: Sier, Vincent Q., et al.
Publicado: (2021)

Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[(18)F]F PET-CT in Patients With Fibrous Dysplasia/McCune–Albright Syndrome
por: van der Bruggen, Wouter, et al.
Publicado: (2021)

Investigating the potential added value of [(18)F]FDG-PET/CT in long COVID patients with persistent symptoms: a proof of concept study
por: Chen, Linda L., et al.
Publicado: (2023)

Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?
por: de Koster, Elizabeth J., et al.
Publicado: (2021)

FDG-PET in colorectal cancer
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2006)

Cerebral [(18)F]-FDOPA Uptake in Autism Spectrum Disorder and Its Association with Autistic Traits
por: Schalbroeck, Rik, et al.
Publicado: (2021)

Letter to the Editor: Interobserver Variability of Heart-to-Mediastinum Ratio in I-123 MIBG Sympathetic Imaging
por: Bulten, Ben F., et al.
Publicado: (2012)

Optimal respiratory-gated [(18)F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma
por: Smeets, Esther M. M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3as0ruhfbbdgcs2ue28ihm2er3